

C型慢性肝炎に対するペグインターフェロン+リバビリン併用療法の有効性を規定する*IL28B*(インターフェロンλ)領域の遺伝子多型(SNPs)





Genome-wide association of *IL28B* with response to pegylated interferon- α and ribavirin therapy for chronic hepatitis C

Yasuhito Tanaka^{1,18}, Nao Nishida^{2,18}, Masaya Sugiyama¹, Masayuki Kurosaki³, Kentaro Matsuura¹, Naoya Sakamoto⁴, Mina Nakagawa⁴, Masaaki Korenaga⁵, Keisuke Hino⁵, Shuhei Hige⁶, Yoshito Ito⁷, Eiji Mita⁸, Eiji Tanaka⁹, Satoshi Mochida¹⁰, Yoshikazu Murawaki¹¹, Masao Honda¹², Akito Sakai¹², Yoichi Hiasa¹³, Shuhei Nishiguchi¹⁴, Asako Koike¹⁵, Isao Sakaida¹⁶, Masatoshi Imamura¹⁷, Kiyooki Ito¹⁷, Koji Yano¹⁷, Naohiko Masaki¹⁷, Fuminaka Sugauchi¹, Namiki Izumi³, Katsushi Tokunaga² & Masashi Mizokami^{1,17}


Tanaka Y, Mizokami M., et al. Nature Genetics 2009

IL28B関連の最近の話題

PEG-IFN/RBV併用療法の効果とIL28B遺伝子多型



IL28Bアレル別のHCV-RNA陰性化率



GWAS

別の因子

ウイルス因子
宿主因子

予測精度の
向上目指す